Bank Hapoalim Bm Novo Nordisk A S Transaction History

Bank Hapoalim Bm

$772 Million
Q1 2024

A detailed history of Bank Hapoalim Bm transactions in Novo Nordisk A S stock. As of the latest transaction made, Bank Hapoalim Bm holds 10,210 shares of NVO stock, worth $1.42 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares

10,210

Previous 11,560 11.68%

Holding current value

$1.42 Million

Previous $1.2 Million 9.62%

% of portfolio

0.17%

Previous 0.16%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	SELL	$102.11 - $135.92 $137,848 - $183,491	-1,350 Reduced 11.68%	10,210 $1.31 Million
Q4 2023 Jan 22, 2024	SELL	$87.78 - $105.45 $237,006 - $284,715	-2,700 Reduced 18.93%	11,560 $1.2 Million
Q3 2023 Oct 24, 2023	BUY	$90.94 - $199.54 $593,838 - $1.3 Million	6,530 Added 84.48%	14,260 $1.3 Million
Q2 2023 Jul 26, 2023	SELL	$155.98 - $172.65 $116,984 - $129,487	-750 Reduced 8.84%	7,730 $1.25 Million
Q1 2023 Apr 25, 2023	SELL	$132.34 - $159.14 $177,335 - $213,247	-1,340 Reduced 13.65%	8,480 $1.35 Million

Q3 2022 Nov 08, 2022	SELL	$95.28 - $116.93 $19,056 - $23,386	-200 Reduced 2.0%	9,820 $978,000
Q1 2022 Apr 28, 2022	SELL	$93.1 - $112.54 $200,165 - $241,961	-2,150 Reduced 17.67%	10,020 $1.11 Million
Q4 2020 Feb 03, 2021	SELL	$63.89 - $73.8 $44,723 - $51,660	-700 Reduced 5.44%	12,170 $850,000
Q3 2020 Nov 12, 2020	SELL	$63.69 - $70.22 $82,797 - $91,286	-1,300 Reduced 9.17%	12,870 $894,000
Q4 2019 Feb 03, 2020	BUY	$49.86 - $58.26 $62,325 - $72,825	1,250 Added 9.67%	14,170 $820,000
Q3 2017 Nov 07, 2017	BUY	$41.15 - $49.22 $308,625 - $369,150	7,500 Added 138.38%	12,920 $622,000
Q2 2017 Aug 11, 2017	BUY	N/A	5,420	5,420 $232,000

Others Institutions Holding NVO

# of Institutions

1,859

Shares Held

310M

Call Options Held

5.29M

Put Options Held

4.93M

View Full List

About NOVO NORDISK A S

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $313B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

More about NVO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Hapoalim Bm, based on Form 13F filings with the SEC.

News

Stay updated on Bank Hapoalim Bm with notifications on news.

Account